Artemis Signs Deal to Create Knockdown Mice for Merck
Artemis Pharmaceuticals said this week that it has signed a deal to develop RNAi-modified genetically engineered mice for use by Merck for in vivo functional analysis of selected disease-related genes.
Under the deal, Merck will provide shRNA sequences that correspond to genes that may play a role in human diseases. Artemis will use the shRNAs and its RNAi technology to generate mice in which the genes are down regulated.
Financial terms of the arrangement were not disclosed.